Biogen och Samsung Bioepis Godkänn med Abbvie tillåta kommersialisering av IMRALDI ™ (Adalimumab biosimilar) i Europa

Biogen Inc. (Nasdaq: BIIB) and its partner Samsung Bioepis announced today an agreement with AbbVie (NYSE: ABBV) for the commercialization of IMRALDI, a biosimilar referencing HUMIRA® (adalimumab). Under terms of the agreement, AbbVie will grant patent licenses for the use and sale of IMRALDI in Europe, on a country-by-country basis, and Biogen and Samsung Bioepis will make royalty payments to AbbVie. The companies have agreed to dismiss all pending patent litigation.

Biogen expects to launch IMRALDI in Europe on October 16, 2018, which will complement its existing portfolio of anti-TNF therapies, BENEPALI™ (etanercept) and FLIXABI™ (infliximab).

Tagged , , , , , . Bookmark the permalink.

About Liz

Att besöka min andra bloggar Spinal Muskelatrofi (SMA)

Comments are closed.